» Articles » PMID: 10769275

Plasma Concentration of Interleukin-6 and the Risk of Future Myocardial Infarction Among Apparently Healthy Men

Overview
Journal Circulation
Date 2000 Apr 19
PMID 10769275
Citations 671
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Interleukin-6 (IL-6) plays a central role in inflammation and tissue injury. However, epidemiological data evaluating the role of IL-6 in atherogenesis are sparse.

Methods And Results: In a prospective study involving 14 916 apparently healthy men, we measured baseline plasma concentration of IL-6 in 202 participants who subsequently developed myocardial infarction (MI) and in 202 study participants matched for age and smoking status who did not report vascular disease during a 6-year follow-up. Median concentrations of IL-6 at baseline were higher among men who subsequently had an MI than among those who did not (1.81 versus 1. 46 pg/mL; P=0.002). The risk of future MI increased with increasing quartiles of baseline IL-6 concentration (P for trend <0.001) such that men in the highest quartile at entry had a relative risk 2.3 times higher than those in the lowest quartile (95% CI 1.3 to 4.3, P=0.005); for each quartile increase in IL-6, there was a 38% increase in risk (P=0.001).This relationship remained significant after adjustment for other cardiovascular risk factors, was stable over long periods of follow-up, and was present in all low-risk subgroups, including nonsmokers. Although the strongest correlate of IL-6 in these data was C-reactive protein (r=0.43, P<0.001), the relationship of IL-6 with subsequent risk remained after control for this factor (P<0.001).

Conclusions: In apparently healthy men, elevated levels of IL-6 are associated with increased risk of future MI. These data thus support a role for cytokine-mediated inflammation in the early stages of atherogenesis.

Citing Articles

Features of the monocyte inflammatory response in patients with premature coronary artery disease.

Blokhina T, Kirichenko T, Markina Y, Khovantseva U, Melnikov I, Guseva O Biophys Rep. 2025; 11(1):12-17.

PMID: 40070664 PMC: 11891073. DOI: 10.52601/bpr.2024.240030.


Tocilizumab Increases Serum Lipids but Does Not Increase Arteriosclerosis, As Measured by Intima-Media Thickness, in Patients With Rheumatoid Arthritis.

Moriyama M, Murakawa Y, Kondo M, Taira M, Sumita Y, Honda M Cureus. 2025; 17(1):e76782.

PMID: 39897309 PMC: 11786537. DOI: 10.7759/cureus.76782.


A review of cutting-edge biomarkers for diagnosing coronary artery disease.

Azami P, Mohammadzadeh S, Seirafi S, Razeghian-Jahromi I Medicine (Baltimore). 2025; 104(4):e41377.

PMID: 39854741 PMC: 11771658. DOI: 10.1097/MD.0000000000041377.


Effects of continuous positive airway pressure treatment on arterial stiffness and inflammatory factors in patients with coronary heart disease complicated with obstructive sleep apnea.

Wang L, Wang Y, Jiao T, Xu L, Ji E, Tapu S J Cardiothorac Surg. 2025; 20(1):59.

PMID: 39799348 PMC: 11724610. DOI: 10.1186/s13019-024-03252-2.


Discordance Between Triglycerides, Remnant Cholesterol and Systemic Inflammation in Patients with Schizophrenia.

Wang J, Kockx M, Pennings G, Lambert T, Chow V, Kritharides L Biomedicines. 2025; 12(12.

PMID: 39767790 PMC: 11673878. DOI: 10.3390/biomedicines12122884.